Several investigators have demonstrated that the assessment of indirect and direct effects is biased in the presence of a cause that is common to both the mediator and the outcome if one has not controlled for this variable in the analysis. However, little work has been done to quantify the bias caused by this type of unmeasured confounding and determine whether this bias will materially affect conclusions regarding mediation. The author developed a sensitivity analysis program to address this crucial issue. Data from 2 well-known studies in the methodological literature on mediation were reanalyzed using this program. The results of mediation analyses were found not to be as vulnerable to the impact of confounding as previously described; however, these findings varied sharply between the 2 studies. Although the indirect effect observed in one study could potentially be due to a cause common to both the mediator and the outcome, such confounding could not feasibly explain the results of the other study. These disparate results demonstrate the utility of the current sensitivity analysis when assessing mediation.
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The assessment of mediation is an important tool for exploring the mechanisms that underlie a particular exposure-disease relation. For example, the identification of a mediator improves the biologic plausibility of a hypothesis while decreasing the probability that results are spurious (1) . Therefore, demonstrating that a hypothesized mediator explains at least part of the relation between exposure and disease strengthens the evidence that the observed exposure-disease association is indeed causal. In a randomized controlled trial, the assessment of mediation is important for evaluating whether a treatment is working as expected (1) . This information can be used to modify an intervention so as to more efficiently impact a particular mediator. Such results can also implicate new interventions that might work through the same mechanism.
Several authors have noted, however, that the assessment of mediation can be biased, which can lead to inaccurate conclusions regarding explanatory pathways. Many of these critiques focus on the possibility of confounding by a cause common to both the mediator and the outcome (2) (3) (4) . Such confounding is illustrated in Figure 1 . Exposure (X) is hypothesized to cause the outcome (Y), both by causing the mediator (M) (indirect effect) and through other mechanisms (direct effect). An unmeasured confounder (C) of the mediatoroutcome relation would bias estimates of the indirect and direct effect and could lead to the appearance of an indirect effect when, in fact, one does not exist. Such a confounder would not bias the total effect. Multiple investigators have used examples to illustrate the bias that can arise as the result of unmeasured confounding of the mediator (3, 5) . On the basis of these examples, they concluded that the decomposition of indirect and direct effects is generally not reliable (6) .
However, the fact that bias can lead to fallible interpretations under illustrative situations is only part of the story. To apply these methodological findings to mediation analyses in the literature, researchers need to know the degree to which a potential confounder might bias an estimate of direct or indirect effect and how strong a confounder would have to be to provide a plausible alternative explanation for observed results (7, 8) . Such information is critical when assessing the vulnerability of results to potential bias.
To date, the methodological work on the magnitude and direction of bias from confounding of the mediator has been limited (8) . Although investigators have demonstrated that confounding of the mediator-disease relation can theoretically pose a problem, the actual extent of this problem has not been addressed. In the present article, I address this need by presenting a sensitivity analysis with which one can quantify the bias due to confounding of the mediator-disease relation. A sensitivity analysis indicates the set of true associations that are consistent with the observed association, given a range of systematic errors. Most importantly, a sensitivity analysis indicates how strong a particular source of bias would have to be to explain the entire observed result. Sensitivity analyses have been developed to assess the impact of several standard biases in epidemiology, including confounding, measurement error, and selection bias (9) (10) (11) (12) .
I developed a sensitivity analysis program for mediation and used it to reassess data from 2 well-known examples of mediation analysis. The first example is from the Lipid Research Clinics Coronary Primary Prevention Trial; the second is from a randomized clinical trial in ophthalmology. Both studies have been used previously to illustrate novel techniques for the assessment of mediation (6, (13) (14) (15) (16) .
MATERIALS AND METHODS
When calculating direct and indirect effects, there is always the possibility that a confounder of the mediatordisease relation has been omitted from the analysis and that this confounder could provide an alternative explanation for the observed results. The purpose of this sensitivity analysis was to determine the impact of such an unmeasured confounder on the observed effects. Specifically, this program yields the adjusted direct or indirect effect that would be consistent with the observed (unadjusted) results, given a confounder of a certain strength, prevalence, and degree of interaction with other variables. By testing a range of confounders, this program determines the strength of confounding necessary to change an investigator's interpretation of the results. This sensitivity analysis was developed using SAS, version 9.2 (SAS Institute, Inc., Cary, North Carolina); relevant code is shown in Web Appendix A (available at http://aje.oxfordjournals.org/).
To focus on the bias caused by confounding of the mediatoroutcome relation, assume that all other biases are absent; these include measurement error, selection bias, and unmeasured confounding of the exposure-disease relation. Random sampling error is also not considered in this sensitivity analysis. All variables in this sensitivity analysis (exposure, mediator, outcome, and unmeasured confounder) are considered to be dichotomous.
Inputs
The primary user-defined inputs required for this sensitivity analysis are relevant observed population proportions. Specifically, the investigator must provide the observed risk of the mediator in the exposed (p(M ¼ 1jX ¼ 1)) and unexposed (p(M ¼ 1jX ¼ 0)) groups and the observed risk of the outcome in the 4 exposure-and mediator-defined
). Note that the above values can easily be calculated using data from a population-based study. When using observational data, one can adjust these proportions for the measured confounders of the exposure-disease relation.
The investigator must also specify the direct or indirect effect of interest: the pure indirect effect (PIE), total indirect effect (TIE), pure direct effect (PDE), or total direct effect (TDE). The decision about which effect to use (direct vs. indirect, total vs. pure) should be based on the particular question that the investigator is asking (1) . The remainder of this article will use the PIE.
The sensitivity analysis also requires the investigator to specify a critical value for the proportion of the total effect (of exposure on outcome) explained by the direct or indirect effect of interest. This is the value beyond which the interpretation of the data would qualitatively change. For example, consider a situation in which the observed PIE explains 40% of the total effect. The investigator might want to know the strength of confounding that would lead to this observed result, when the adjusted PIE would only explain 10% of the total effect. The critical value in this case would be 0.1. The default critical value for the sensitivity analysis is 0.1; however, this input may be changed by the investigator if desired.
Finally, specified characteristics of the unmeasured confounder (the prevalence of the confounder and the degree to which the confounder interacts with other variables) are required inputs for computations. These characteristics are generally not known by the investigator. As a default, the sensitivity analysis tests a range of confounder prevalences (range, 5%-95%). However, if the prevalence of a particular unmeasured confounder is known (i.e., from external data or a subset of the study population), the investigator can specify the confounder prevalence of interest.
The program tests both additive and multiplicative models, with regards to the confounder. In the additive model, the confounder-mediator risk difference (RD CM ) is the same regardless of exposure status; similarly, the confounderdisease risk difference does not differ depending on exposure or mediator status. In the multiplicative model, the confounder-mediator and confounder-disease risk ratios do not differ across strata of other variables. Note that this sensitivity analysis is nonparametric, so no particular interaction model is assumed with regards to the exposure and mediator.
Outputs
This sensitivity analysis has 4 basic outputs. First, the observed indirect (and direct) effects are calculated from observed population risks. Second, the range of testable confounder-mediator risk ratios (RR CM ) and confounderdisease risk ratios is determined. Third, for each possible confounder-mediator risk ratio (between 0.05 and 20), the confounder-outcome risk ratio (RR CY ) that would be consistent with the specified critical value of the indirect (or direct) effect is determined. Fourth, for each possible pair of risk ratios (confounder-mediator and confounder-disease), the adjusted indirect (and direct) effects are given.
On the basis of the relevant observed risks, the sensitivity analysis first calculates the observed estimate of the direct or indirect effect of interest (PIE, TIE, PDE, or TDE). These effects and methods for their estimation have been described previously (3, 17, 18) . The PIE is the effect of exposure if its only action were to cause the mediator. Several equivalent methods have been described for estimating the PIE based on the observed data (15, 17, 18) . The PIE is estimated as the effect of the exposure on the mediator multiplied by the effect of the mediator on the outcome, in the absence of exposure:
This observed measure can also be expressed as a proportion of the total effect (proportion explained, PE). The PE PIE is calculated by dividing the PIE by the total effect of exposure on disease.
On the basis of the relevant inputs, the sensitivity analysis determines the most extreme confounder-mediator and confounder-outcome risk ratios that are possible, given the current bias model. These limits are based on the fact that the proportion of individuals with the mediator, given a particular value for the exposure and confounder (p(M ¼ 1jX ¼ x, C ¼ c)), must be between 0 and 1. Similarly, the risk of the outcome in each exposure-, mediator-, and confounder-
) must be between 0 and 1. This basic tenet places limits on the strength of confounding that is possible by a single unmeasured confounder, given the observed data and specified confounder characteristics (19) . The equations for the additive model are found in Table 1 ; both equations for the multiplicative model and derivations of these equations are shown in Web Appendix B.
The sensitivity analysis tests a range of possible confounder-mediator risk ratios (RR CMjX¼0 ), from 0.05 to 20. For each confounder-mediator risk ratio, the program calculates the confounder-outcome risk ratio that would be consistent with the critical value of the PE PIE (if such a risk ratio exists). For the additive model, this equation for the confounder-outcome risk difference (RD CY ) is
From this value, the critical confounder-outcome risk ratio can be calculated. Equations for the multiplicative model and derivations of the equations are shown in Web Appendix B.
For each confounder-mediator risk ratio, a range of positive confounder-outcome relations are tested (RR CYjX¼0, M¼0 ¼ 1-RR CYjX¼0, M¼0 ¼ 20). For each confounding scenario (i.e., confounder prevalence, interaction model, and confounder-mediator and confounder-disease risk ratios), the sensitivity analysis derives the adjusted PIE that is consistent with the observed risks. If a particular confounding scenario is of interest, the investigator can alternatively specify a confounder-mediator and confounder-disease risk ratio and the program will return the appropriate adjusted PIE (assuming that this particular confounding scenario is possible).
To calculate the indirect or direct effect, the sensitivity analysis first determines the prevalence of the mediator in each exposure-and confounder-defined subgroup (P(M ¼ 1jX ¼ x, C ¼ c)), the prevalence of the confounder in each exposureand mediator-defined subgroup (P(C ¼ 1jX ¼ x, M ¼ m)), and the prevalence of the outcome in each exposure-, mediator-, and confounder-defined subgroup (
. Equations for the additive interaction model are given 
in Table 2 ; equations for the multiplicative model, as well as the relevant derivations, are given in Web Appendix B. On the basis of these values, the adjusted PIE that would be consistent with the observed data, given a particular confounder prevalence and strength, can be calculated as
I used the sensitivity analysis to reassess data from 2 examples that have been previously evaluated in the mediation literature. I assessed the amount of confounding that is possible (given the assumptions of the model) and whether this confounding could plausibly change the investigator's interpretation of the observed results. I present results for the pure indirect effect (PIE); this sensitivity analysis can also be utilized to obtain results for the other natural effects (TIE, PDE, and TDE).
RESULTS

Example 1
The first example is taken from the work of Freedman et al. (13) and comes from the Lipid Research Clinics Coronary Primary Prevention Trial. In this randomized controlled trial, investigators found that cholestyramine decreased the risk of coronary heart disease (CHD). Freedman et al. were interested in whether a decrease in the prevalence of hypercholesterolemia could explain this difference. If randomization worked properly, confounding of the exposure-disease relation would not be an issue. However, randomization does not prevent confounding of the mediatordisease relation (3) .
The data obtained from this study, as summarized by Kaufman et al. (6) , represent the inputs for the current sensitivity analysis. They include 1) the proportion given cholestyramine (P (X¼1) ¼ 0.5); 2) the risk of elevated cholesterol in the treated (P (M¼1jX¼1) ¼ 0.193) and placebo (P (M¼1jX¼0) ¼ 0.392) groups; and 3) the risk of CHD in treatment-assigned individuals with high cholesterol (P (Y¼1jX¼1, M¼1) ¼ 0.0904), treatment-assigned individuals with low cholesterol (P (Y¼1jX¼1, M¼0) ¼ 0.0637), placebo-assigned individuals with high cholesterol (P (Y¼1jX¼0, M¼1) ¼ 0.1091), and placebo-assigned individuals with low cholesterol (P (Y¼1jX¼0, M¼0) ¼ 0.0737).
From these inputs, the sensitivity analysis can be used to calculate the total effect of cholestyramine on CHD risk (RD XY ¼ À0.0187) and the indirect effect of interest (PIE obs ¼ À0.00704). These results indicate that 37.6% of the effect of cholestyramine on CHD is due to lowered serum cholesterol (PE PIE(obs) ¼ 0.376). On the basis of this result, one would conclude that the observed association is at least partially explained by changes in serum cholesterol levels; this is consistent with previous work (13) . However, how vulnerable are these results to potential confounding of the mediator-disease relation? The remainder of the results will describe 1) the range of possible confounding (given the current bias model) and 2) the amount of confounding necessary to substantially change the interpretation of the observed results. Table 3 shows the range of possible confounder-mediator and confounder-disease risk ratios for the additive interaction model for confounder prevalences ranging from 5% to 95%. For simplicity, only positive confounder-mediator risk ratios are shown; the sensitivity analysis also returns similar results for negative confounders (i.e., confounder-mediator risk ratios less than 1). The maximum possible confoundermediator risk ratios are shown in the second column; the corresponding maximum confounder-outcome risk ratios are shown in the third column. Table 3 also indicates the confounding strength that would be consistent with an adjusted PE PIE of 10%, given observed results and an additive interaction model. For example, a confounder with a prevalence of 0.2, RR CM ¼ 2, 
Abbreviation: RD, risk difference.
and RR CY ¼ 2.97 would lead to the observed results (PE PIE(obs) ¼ 0.376) even with an adjusted PE PIE of only 10%. The observed indirect effect in this example could be explained by an unmeasured confounder, and results should be interpreted with caution. For each possible confounder-mediator risk ratio (between 0.05 and 20) and confounder-outcome risk ratio (between 1 and 20), the sensitivity analysis calculates the PE PIE that would be consistent with the observed results and the confounder characteristics. These results are displayed in a series of figures for each interaction model and confounder prevalence. Figure 2 shows the results from the additive (Figure 2A ) and multiplicative ( Figure 2B ) models for a confounder prevalence of 40%. Each line represents a different confounder-mediator risk ratio, as labeled in the legend; the x-axis of each of these graphs is the strength of the confounder-disease risk ratio. The deviation between the observed PE PIE (labeled as observed PIE) and the true PE PIE indicates the impact of confounding for a particular confounder prevalence, confounder-mediator risk ratio, and confounder-disease risk ratio.
This figure provides a visual correlate for the results found in Table 3 . From Figure 2 , it is evident that a single confounder, found in 40% of the population, could explain the observed results. The additive and multiplicative models are similar in terms of the degree of confounding necessary to explain results, but they differ sharply regarding the degree of confounding that is possible. As shown in Figure 2A , the maximum confounder-mediator risk ratio possible in the additive model is 3.42; in Figure 2B , confounder-mediator risk ratios exceeding 20 are possible. For a complete set of figures, see Web Appendix C.
Example 2
The second example is taken from a randomized controlled trial in which investigators evaluated whether the unexpected harmful effect of interferon-a on vision at 1 year was explained by loss of vision at 6 months. The purpose of the present analysis was to determine whether 2 or more lines of vision loss at 6 months would be a good surrogate outcome for 3 or more lines of vision loss at 1 year in the context of interferon-a exposure. This example has been used by several investigators to develop methods for the assessment of mediation (14) (15) (16) . Because that study was Figure 2 . Impact of an unmeasured confounder (P (C¼1) ¼ 0.4) on the pure indirect effect (PIE) in the coronary heart disease example. Each of the lines represents the adjusted PIE that would be consistent with the observed PIE, given particular confounder-outcome and confounder-mediator (RR CM ) risk ratios. A) Results from the additive interaction model; B ) results from the multiplicative model. For each tested confounder prevalence (assuming the additive model), the maximum possible confounder-mediator and confounderoutcome risk ratios are displayed. For each confounder prevalence and possible confounder-mediator risk ratio, the right column shows the confounder-outcome risk ratio consistent with a proportion explained by the pure indirect effect of 10%.
b Maximum possible confounder-mediator risk ratio. c Given confounder prevalence and confounder-mediator risk ratio, no such confounder-outcome risk ratio exists. a randomized controlled trial, confounding of the exposuredisease relation was generally not a concern; however, such randomization does not prevent confounding of the mediatordisease relation.
The data obtained from that study have been summarized by Ditlevsen et al. (16) ; the observed results of the study represent the inputs for the current sensitivity analysis. They include 1) the proportion given interferon-a (P (X¼1) ¼ 0.46); 2) the risk of vision loss of 2 or more lines at 6 months in the treated (P (M¼1jX¼1) ¼ 0.54) and placebo (P (M¼1jX¼0) ¼ 0.369) groups; and 3) the risk of vision loss of 3 or more lines at 1 year in treatment-assigned individuals with early vision loss (P (Y¼1jX¼1, M¼1) ¼ 0.809), treatment-assigned individuals with no early vision loss (P (Y¼1jX¼1, M¼0) ¼ 0.225), placebo-assigned individuals with early vision loss (P (Y¼1jX¼0, M¼1) ¼ 0.789), and placebo-assigned individuals with no early vision loss (P (Y¼1jX¼0, M¼0) ¼ 0.139).
With these inputs, the sensitivity analysis can be used to calculate the total effect of interferon-a on vision loss at 1 year (RD XY ¼ 0.1614) and the indirect effect of interest (PIE obs ¼ 0.1113). These results indicate that the PIE explains 69% of the total effect (PE PIE (Obs) ¼ 0.690). One would thus conclude that the observed association between interferon-a and vision loss at 1 year is at least partially explained by vision loss at 6 months. The goal of the present sensitivity analysis was to determine how vulnerable these results were to potential confounding of the mediator-disease relation.
The range of possible confounder-mediator and confounderoutcome risk ratios for the additive model are given in Table 4 . For relatively rare confounders (prevalence ¼ 5% or 20%), the possible range of risk ratios is quite limited. For more prevalent confounders (prevalence ¼ 40% or greater), wider ranges of both confounder-mediator and confounder-outcome risk ratios are possible.
Out of all the confounding scenarios tested, however, only 1 would be consistent with a PE PIE of 10% and thus conceivably change the investigator's interpretation of the observed results (Table 4) . This scenario involves a relatively prevalent confounder (found in 40% of the population) with a confounder-mediator risk ratio of 13.30 (the maximum possible RR CM ) and a confounder-outcome risk ratio of 12.33 (also close to the maximum possible RR CY ). Although such a scenario is certainly possible, this represents an extremely strong confounder, with risk ratios greater than 10. In addition, these risk ratios approach the maximum possible risk ratios, indicating that the risk of the mediator (or outcome) in a particular subgroup is approaching 0 or 1; such a situation is unlikely under most circumstances.
The results are visually displayed in a series of figures (Web Appendix C). For comparison with the CHD results, Figure 3 shows the impact of a confounder with a prevalence of 40% on the vision loss data, given both the additive ( Figure 3A ) and multiplicative ( Figure 3B ) models. Figure 3A illustrates the confounding scenario described above that would be consistent with a critical value for the PE PIE . Figure 3B illustrates that, given the multiplicative model, such confounding strengths are not possible. Thus, assuming the accuracy of the current bias model, a single dichotomous confounder with no interaction (on the risk ratio scale) between exposure (to cause the mediator) and exposure or mediator (to cause the outcome) could not possibly explain the observed results.
DISCUSSION
I have developed a sensitivity analysis program to evaluate the range of true mediational quantities that are consistent with the observed data, given a single unmeasured confounder of the mediator-outcome relation. I applied this program to the results of 2 well-known examples of mediation in epidemiology. In both examples, an appreciable proportion of the total effect was explained by the indirect effect. This approach illuminates a number of issues and provides a tool that might be used in future applications.
The utility of this program is illustrated by the disparate results it provides for the effects of confounding in the 2 study examples. In the CHD example, although a sizeable proportion of the total effect is attributable to the indirect For each tested confounder prevalence (assuming the additive model), the maximum possible confounder-mediator and confounderoutcome risk ratios are displayed. For each confounder prevalence and possible confounder-mediator risk ratio, the right column shows the confounder-outcome risk ratio consistent with a proportion explained by the pure indirect effect of 10%.
b Given the confounder prevalence and confounder-mediator risk ratio, no such confounder-outcome risk ratio exists.
c Maximum possible confounder-mediator risk ratio.
effect of interest (38%), this entire effect could be explained by a moderately prevalent confounder (prevalence ¼ 20%-40%) with a relatively strong relation to both the mediator and the outcome (e.g., RR CM ¼ 2, RR CY ¼ 2.97). This is not a weak confounder, but it might be considered reasonable in many situations. The plausibility of such an alternative explanation would depend on the particular subject matter and whether researchers had adjusted for known causes common to both the mediator and outcome in the analysis. In the vision loss example, the majority of the total effect is explained by the indirect effect of interest (69%). It is much more difficult to fully explain away this indirect effect. In the absence of a large true indirect effect, the observed results would only be produced by a prevalent confounder (prevalence ¼ 40%) given perfect additivity and under extreme circumstances (e.g., RR CM ¼ 13, RR CY ¼ 12).
The current approach uses a nonparametric model that does not specify a particular relation between variables. There are several key advantages to this approach. First, this approach clarifies which confounder strengths are possible and which are not (based on the observed data, confounder prevalence, and interaction model). This is important information, and it limits the range of confounder prevalences and strengths about which one has to worry. Second, this method illustrates that the chosen model (additive or multiplicative) can affect both whether a given confounder is possible and its impact on results. Because a nonparametric approach allows flexibility with regard to the specified interaction model, a wider range of confounding can be assessed.
I have developed a sensitivity analysis program that is useful for determining the degree to which observed results can be explained by confounding of the mediator-disease relation. This program can be used to assess the vulnerability of other mediation analyses to the confounding of the mediator-disease relation. The parameters of this program (confounder prevalences, strengths, and interaction models) can be modified based on subject matter knowledge to fit a particular example. The relevant macros have been provided in Web Appendix A.
In the present analysis, I have attempted to assess the impact of bias due to a single cause common to both the mediator and the disease that is not associated with exposure. In future work, investigators might broaden this inquiry to assess the bias caused by multiple confounders of the mediator-disease relation. This work should also consider the impact of common causes of exposure, mediator, and disease and/or confounders of the mediator-disease relation that are consequences of exposure. In addition, other potential limitations of mediation analysis, such as measurement error and low power, should be addressed. Finally, current work has assumed that all variables are dichotomous; future work might extend these methods to more general settings.
In conclusion, I have shown that the bias due to confounding of the mediator-outcome relation is limited, but the extent of this limitation is largely example-specific. To this end, I have developed a sensitivity analysis program to evaluate the impact of such confounding. I hope that this program will be used by future investigators to ask the very important question: How strong would confounding of the mediator-outcome relation have to be to explain the observed results? It is clear that unmeasured confounding of the mediator causes bias; this tool will indicate, on a caseby-case basis, the magnitude and direction of the bias that such confounding causes in the real world. 
